Biological agents and respiratory infections: Causative mechanisms and practice management

Respiratory Investigation
Noboru Takayanagi

Abstract

Biological agents are increasingly being used to treat patients with immune-mediated inflammatory disease. In Japan, currently approved biological agents for patients with rheumatoid arthritis (RA) include tumor necrosis factor inhibitors, interleukin-6 receptor-blocking monoclonal antibody, and T-cell costimulation inhibitor. Rheumatologists have recognized that safety issues are critical aspects of treatment decisions in RA. Therefore, a wealth of safety data has been gathered from a number of sources, including randomized clinical trials and postmarketing data from large national registries. These data revealed that the most serious adverse events from these drugs are respiratory infections, especially pneumonia, tuberculosis, nontuberculous mycobacteriosis, and Pneumocystis jirovecii pneumonia, and that the most common risk factors associated with these respiratory infections are older age, concomitant corticosteroid use, and underlying respiratory comorbidities. Because of this background, in 2014, the Japanese Respiratory Society published their consensus statement of biological agents and respiratory disorders. This review summarizes this statement and adds recent evidence, especially concerning respiratory infections in...Continue Reading

References

Sep 1, 1991·The Journal of Experimental Medicine·P S LinsleyJ A Ledbetter
Jan 1, 1988·Annual Review of Immunology·T Kishimoto, T Hirano
May 1, 1987·Clinical Immunology and Immunopathology·E P BolingR L Wilder
Jun 15, 1985·British Medical Journal·O MutruK Koota
Mar 1, 1970·Arthritis and Rheumatism·J UddinH G Kelly
May 1, 1984·British Journal of Rheumatology·P PriorC F Hawkins
Jun 1, 1995·Seminars in Arthritis and Rheumatism·A M BoerboomsL B van de Putte
Nov 1, 1994·Radiology·M Remy-JardinB Delcambre
Jul 1, 1994·American Journal of Respiratory and Critical Care Medicine·G P LeMense, S A Sahn
Apr 1, 1994·Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·S O'ReillyL Clancy
Jan 1, 1994·Scandinavian Journal of Rheumatology·A A StengerH R Pasma
Apr 1, 1994·Arthritis and Rheumatism·F WolfeM A Cathey
Apr 1, 1994·Annals of the Rheumatic Diseases·M J van der VeenJ W Bijlsma
Mar 25, 1998·The Journal of Antimicrobial Chemotherapy·M R Haeney
Nov 25, 1998·Proceedings of the National Academy of Sciences of the United States of America·U G WagnerJ J Goronzy
Aug 2, 2000·Proceedings of the National Academy of Sciences of the United States of America·K KoetzC M Weyand
Apr 17, 2002·Seminars in Hematology·Gordon Starkebaum
Aug 28, 2002·Immunity·Alison V CollinsSimon J Davis
Oct 2, 2002·Arthritis and Rheumatism·Michele F DoranSherine E Gabriel
Feb 6, 2003·British Journal of Pharmacology·Darren C PhillipsHelen R Griffiths
Apr 1, 2003·Expert Opinion on Investigational Drugs·Paul Emery
Oct 1, 1953·The New England Journal of Medicine·S COBBW BAUER
Nov 14, 2003·The New England Journal of Medicine·Joel M KremerLarry W Moreland
May 14, 2004·The New England Journal of Medicine·C Robert Horsburgh
Aug 13, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Aparna K MohanM Miles Braun
Feb 17, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Carolina Garcia VidalJavier Garau
May 10, 2005·Annals of the Rheumatic Diseases·M HakodaS Fujiwara
Oct 29, 2005·Arthritis and Rheumatism·Joachim ListingAngela Zink
Nov 26, 2005·Annals of the Rheumatic Diseases·N P RiksenG A Rongen
Mar 15, 2006·Annals of the Rheumatic Diseases·B N Cronstein
Jul 14, 2006·Annals of the Rheumatic Diseases·T YamadaH Yamanaka
Apr 13, 2007·Digestive Diseases and Sciences·Nirmal Kaur, Thomas C Mahl
Feb 5, 2008·Mayo Clinic Proceedings·Sotirios TsiodrasDimitrios P Kontoyiannis
Apr 19, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kevin L WinthropUNKNOWN Infectious Diseases Society of America Emerging Infections Network
Jul 24, 2008·Annals of the Rheumatic Diseases·A ZinkD P M Symmons

❮ Previous
Next ❯

Related Concepts

Related Feeds

Castleman Disease

Castleman disease is a rare disorder that involves an overgrowth of cells in the lymph nodes. Unicentric Castleman disease affects one lymph node, usually in the chest or abdomen. Multicentric Castleman disease affects multiple lymph nodes, commonly located in the neck, collarbone, underarm and groin areas. Discover the latest research on Castleman disease here.

Aspergillosis (ASM)

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aspergillosis

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.